Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 3c, Slight Miss on Revenues; Updates FY17 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $214.44 -0.71%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
IEP, XPRO, GEF, More
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
IEP, XPRO, GEF, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.31, $0.03 worse than the analyst estimate of $2.34. Revenue for the quarter came in at $376 million versus the consensus estimate of $377.02 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2017 EPS of $10.70-$11.30, versus the consensus of $11.12. Jazz Pharmaceuticals sees FY2017 revenue of $1.625-1.7 billion, versus the consensus of $1.67 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- Grab Holdings (GRAB) Misses Q3 EPS by 5c; raises guidance
- Sinda Ltd. (SIND) Reports Q3 Loss of $0.10
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
